• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly.

作者信息

Chan Johan, Kanesvaran Ravindran

机构信息

National Cancer Centre Singapore, 11, Hospital Drive, Singapore 169610, Singapore.

出版信息

Ann Transl Med. 2019 Dec;7(Suppl 8):S383. doi: 10.21037/atm.2019.12.76.

DOI:10.21037/atm.2019.12.76
PMID:32016101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6976496/
Abstract
摘要

相似文献

1
The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly.免疫检查点抑制剂（ICI）在老年转移性非小细胞肺癌治疗中的作用。
Ann Transl Med. 2019 Dec;7(Suppl 8):S383. doi: 10.21037/atm.2019.12.76.
2
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗时抗生素的预测影响：抗生素免疫检查点抑制剂在晚期 NSCLC 中的应用。
Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. doi: 10.1007/s00280-019-03993-1. Epub 2019 Nov 19.
3
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.免疫检查点抑制剂在老年非小细胞肺癌患者中的疗效和安全性的真实世界数据。
Cancer Med. 2023 May;12(10):11525-11541. doi: 10.1002/cam4.5889. Epub 2023 Mar 31.
4
Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors.免疫检查点抑制剂时代转移性肾细胞癌患者总生存的变化。
Cancer Epidemiol. 2024 Oct;92:102639. doi: 10.1016/j.canep.2024.102639. Epub 2024 Aug 14.
5
Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.多原发恶性肿瘤患者对免疫检查点抑制剂（ICI）治疗的不同反应：机器人辅助部分肾切除术（RP）后出现的 PD-L1 阴性输尿管和肺转移的透明细胞肾细胞癌，对 ICI 治疗后进展，而同步 PD-L1 阳性原发性肺鳞癌对 ICI 治疗反应良好：病例报告。
World J Surg Oncol. 2023 Feb 6;21(1):37. doi: 10.1186/s12957-023-02920-2.
6
Efficacy of immune checkpoint inhibitor therapy in patients with fusion-positive non-small-cell lung cancer.免疫检查点抑制剂治疗融合阳性非小细胞肺癌患者的疗效。
Immunotherapy. 2021 Aug;13(11):893-904. doi: 10.2217/imt-2021-0035. Epub 2021 Jun 18.
7
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.同步免疫检查点抑制剂和立体定向放射外科治疗非小细胞肺癌、黑色素瘤和肾细胞癌的脑转移。
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5.
8
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.转移性 Merkel 细胞癌患者停止免疫检查点抑制剂治疗后的应答持久性：一项回顾性多中心 DeCOG 研究。
Cancer Immunol Immunother. 2021 Nov;70(11):3313-3322. doi: 10.1007/s00262-021-02925-4. Epub 2021 Apr 18.
9
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.免疫检查点抑制剂单药治疗预处理老年非小细胞肺癌患者的疗效和安全性。
Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771. doi: 10.1007/s00280-020-04055-7. Epub 2020 Mar 19.
10
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.晚期泌尿生殖系统恶性肿瘤患者接受免疫检查点抑制剂治疗的结局特征。
Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23.

引用本文的文献

1
Narrative review of immunotherapy and radiation therapy in elderly patients.老年患者免疫治疗与放射治疗的叙述性综述
Transl Cancer Res. 2021 May;10(5):2620-2631. doi: 10.21037/tcr-20-2637.

本文引用的文献

1
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
2
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.评估晚期非小细胞肺癌免疫治疗患者结局的真实世界终点的探索性分析
JCO Clin Cancer Inform. 2019 Jul;3:1-15. doi: 10.1200/CCI.18.00155.
3
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).纳武利尤单抗治疗晚期非小细胞肺癌患者的安全性、疗效以及患者报告的健康相关生活质量和症状负担，包括 70 岁或以上或体能状态不佳的患者（CheckMate 153）。
J Thorac Oncol. 2019 Sep;14(9):1628-1639. doi: 10.1016/j.jtho.2019.05.010. Epub 2019 May 20.
4
Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.体能状态为2的非小细胞肺癌患者的免疫治疗：证据匮乏情况下的临床决策
J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17.
5
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
6
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.
7
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.FDA 对 PD-1/PD-L1 阻断抗体临床试验中转移性非小细胞肺癌老年患者生存情况的分析。
Semin Oncol. 2018 Aug;45(4):220-225. doi: 10.1053/j.seminoncol.2018.08.007. Epub 2018 Oct 31.
8
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
9
Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research.老年晚期癌症患者的免疫治疗：对临床决策和未来研究的启示。
Am Soc Clin Oncol Educ Book. 2018 May 23;38:400-414. doi: 10.1200/EDBK_201435.
10
Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer.功能年龄与实际年龄：老年癌症患者的评估以指导决策。
Lancet Oncol. 2018 Jun;19(6):e305-e316. doi: 10.1016/S1470-2045(18)30348-6. Epub 2018 Jun 1.